WO2003089922A8 - Method for detecting ligands and targets in a mixture - Google Patents

Method for detecting ligands and targets in a mixture

Info

Publication number
WO2003089922A8
WO2003089922A8 PCT/US2003/011799 US0311799W WO03089922A8 WO 2003089922 A8 WO2003089922 A8 WO 2003089922A8 US 0311799 W US0311799 W US 0311799W WO 03089922 A8 WO03089922 A8 WO 03089922A8
Authority
WO
WIPO (PCT)
Prior art keywords
matrix
target
targets
ligand
complex
Prior art date
Application number
PCT/US2003/011799
Other languages
French (fr)
Other versions
WO2003089922A1 (en
Inventor
David J Hammond
Julia Tait Lathrop
Original Assignee
American Nat Red Cross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Nat Red Cross filed Critical American Nat Red Cross
Priority to CA002482529A priority Critical patent/CA2482529A1/en
Priority to JP2003586604A priority patent/JP4585766B2/en
Priority to EP03747009A priority patent/EP1495318A4/en
Priority to AU2003231731A priority patent/AU2003231731A1/en
Publication of WO2003089922A1 publication Critical patent/WO2003089922A1/en
Publication of WO2003089922A8 publication Critical patent/WO2003089922A8/en
Priority to HK06102446.0A priority patent/HK1082040A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Abstract

The invention provides a method of charaterizing a target that binds to a ligand. The method comprises providing ligands, optionally attached to a support, and contacting the ligands with targets to allow at least one target to bind to at least one ligand. The method further comprises immobilizing the resulting complexes in a first matrix, such that each complex has a different position within the first matrix, and transferring the target of the complex to a second matrix. The position of the target within the second matrix corresponds to the position of the ligand-support complex within the first matrix. The target on the second matrix is then detected.
PCT/US2003/011799 2002-04-15 2003-04-14 Method for detecting ligands and targets in a mixture WO2003089922A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002482529A CA2482529A1 (en) 2002-04-15 2003-04-14 Method for detecting ligands and targets in a mixture
JP2003586604A JP4585766B2 (en) 2002-04-15 2003-04-14 Method for detecting ligands and targets in a mixture
EP03747009A EP1495318A4 (en) 2002-04-15 2003-04-14 Method for detecting ligands and targets in a mixture
AU2003231731A AU2003231731A1 (en) 2002-04-15 2003-04-14 Method for detecting ligands and targets in a mixture
HK06102446.0A HK1082040A1 (en) 2002-04-15 2006-02-23 Method for detecting ligands and targets in a mixture

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37209102P 2002-04-15 2002-04-15
US60/372,091 2002-04-15

Publications (2)

Publication Number Publication Date
WO2003089922A1 WO2003089922A1 (en) 2003-10-30
WO2003089922A8 true WO2003089922A8 (en) 2004-05-06

Family

ID=29250792

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2003/011799 WO2003089922A1 (en) 2002-04-15 2003-04-14 Method for detecting ligands and targets in a mixture
PCT/US2003/011798 WO2003088990A1 (en) 2002-04-15 2003-04-14 Plasma protein-binding ligands

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2003/011798 WO2003088990A1 (en) 2002-04-15 2003-04-14 Plasma protein-binding ligands

Country Status (8)

Country Link
US (4) US7223734B2 (en)
EP (2) EP1495318A4 (en)
JP (1) JP4585766B2 (en)
CN (1) CN100525829C (en)
AU (2) AU2003225008A1 (en)
CA (2) CA2482529A1 (en)
HK (1) HK1082040A1 (en)
WO (2) WO2003089922A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US20050037430A1 (en) * 2000-03-29 2005-02-17 Biotempt B.V. Methods and uses for protein breakdown products
US7365173B2 (en) * 2002-02-04 2008-04-29 American National Red Cross Method for the production of pure virally inactivated butyrylcholinesterase
US20060275753A1 (en) * 2002-04-15 2006-12-07 Hammond David J Recovery of analytes using combinatorial libraries
US20060275829A1 (en) * 2002-04-15 2006-12-07 Hammond David J Combinatorial library for proteomic investigations
AU2003225008A1 (en) * 2002-04-15 2003-11-03 American National Red Cross Plasma protein-binding ligands
US20070015230A1 (en) * 2002-04-15 2007-01-18 Hammond David J Identification and characterization of analytes from whole blood
US20030232379A1 (en) * 2002-06-14 2003-12-18 Amorese Douglas A. Methods of performing array based assays and compositions for practicing the same
CA2491969A1 (en) * 2002-07-11 2004-01-22 The American National Red Cross Method for identifying individual active entities from complex mixtures
US8216854B2 (en) * 2003-01-07 2012-07-10 Biotex, Inc. Device and method for measuring analytes
US7510848B2 (en) * 2003-04-04 2009-03-31 North Carolina State University Prion protein binding materials and methods of use
AU2004229535A1 (en) * 2003-04-14 2004-10-28 Pathogen Removal And Diagnostic Technologies, Inc. Method for identifying ligands specific for structural isoforms of proteins
EP1616025B1 (en) 2003-04-17 2007-09-12 The American National Red Cross Fluorescent substrates for detecting organophosphatase enzyme activity
US7422696B2 (en) * 2004-02-20 2008-09-09 Northwestern University Multicomponent nanorods
US20050277205A1 (en) * 2004-02-20 2005-12-15 Ki-Bum Lee Multicomponent magnetic nanorods for biomolecular separations
EP1580559B1 (en) * 2004-03-23 2013-12-25 Bio-Rad Laboratories, Inc. Methods for reducing the variance between analyte concentrations taken from complex sample mixtures
EA010202B1 (en) * 2004-06-09 2008-06-30 Пэтоджен Римувал Энд Дайэгностик Текнолоджиз Инк. Device and method for removing target agents from a sample
GB0414825D0 (en) * 2004-07-02 2004-08-04 Biostatus Ltd Gel formulations and uses thereof
ATE461211T1 (en) * 2004-12-23 2010-04-15 Novo Nordisk As LIGANDS WITH ANTIBODY BINDING AFFINITY
JP4841618B2 (en) * 2005-03-23 2011-12-21 バイオ−ラッド ラボラトリーズ インコーポレーティッド Methods for purifying proteins
US20090247421A1 (en) * 2005-03-23 2009-10-01 Egisto Boschetti Diverse chemical libraries bound to small particles with paramagnetic properties
JP2008538112A (en) * 2005-03-23 2008-10-09 バイオ−ラッド ラボラトリーズ インコーポレーティッド Diverse chemical libraries bound to small particles with paramagnetic properties
EP1734367A1 (en) * 2005-06-14 2006-12-20 Cellzome Ag Process for the identification of novel enzyme interacting compounds
EP1946121A2 (en) * 2005-10-27 2008-07-23 Yale University, Inc. Urinary proteomic biomarker patterns in preeclampsia
CN102626610B (en) * 2006-01-06 2014-10-01 Emd密理博公司 Affinity chromatography matrices and methods of making and using the same
US20070287991A1 (en) * 2006-06-08 2007-12-13 Mckay William F Devices and methods for detection of markers of axial pain with or without radiculopathy
GB0623607D0 (en) * 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
US20130224730A1 (en) * 2009-11-18 2013-08-29 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Peptide ligands
GB201201751D0 (en) * 2012-02-01 2012-03-14 Haemostatix Ltd Haemostatic wound dressing
EP3514543B1 (en) * 2013-11-07 2021-05-05 Boston Cell Standards LLC Quantitative controls and calibrators for cellular analytes
EP3069141A4 (en) * 2013-11-15 2017-05-10 President and Fellows of Harvard College Methods and assays for factor viii activity
EP4159754A1 (en) * 2014-05-15 2023-04-05 Cleveland Heartlab, Inc. Compositions and methods for purification and detection of hdl and apoa1
CN109975467B (en) * 2017-12-28 2023-05-02 贵州中烟工业有限责任公司 Method for measuring epoxypropanol in main stream smoke of cigarette

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06100604B2 (en) * 1985-06-06 1994-12-12 和光純薬工業株式会社 Fraction detection reagent kit for α-fetoprotein and fraction detection method
JPH0724768B2 (en) * 1985-11-07 1995-03-22 味の素株式会社 Afinophoa based on polyamino acid
US5011686A (en) * 1987-09-21 1991-04-30 Creative Biomolecules, Inc. Thrombus specific conjugates
US5133866A (en) * 1988-03-24 1992-07-28 Terrapin Technologies, Inc. Method to identify analyte-bending ligands
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5498538A (en) 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5235039A (en) 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
US5639603A (en) 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US5236039A (en) * 1992-06-17 1993-08-17 General Electric Company Balanced-line RF electrode system for use in RF ground heating to recover oil from oil shale
AU4779493A (en) * 1992-07-21 1994-02-14 Bunsen Rush Laboratories Inc. Oligomer library formats and methods relating thereto
NZ267843A (en) 1993-05-27 1997-10-24 Selectide Corp Libraries of synthetic test compound attached to separate phase synthesis supports
US5840485A (en) 1993-05-27 1998-11-24 Selectide Corporation Topologically segregated, encoded solid phase libraries
CA2142985A1 (en) * 1993-06-25 1995-01-05 Kenji Shibata Endothelin-antagonizing peptide
US5532167A (en) * 1994-01-07 1996-07-02 Beth Israel Hospital Substrate specificity of protein kinases
US5856083A (en) 1994-05-06 1999-01-05 Pharmacopeia, Inc. Lawn assay for compounds that affect enzyme activity or bind to target molecules
US5688997A (en) 1994-05-06 1997-11-18 Pharmacopeia, Inc. Process for preparing intermediates for a combinatorial dihydrobenzopyran library
US5834318A (en) * 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
SE9502286D0 (en) 1995-06-22 1995-06-22 Pharmacia Ab Process for detection, quantification and / or identification of a peptide
EP0783253B1 (en) * 1995-07-26 2002-10-23 Firmenich Sa Flavoured products and method for preparing same
US5723579A (en) 1996-02-02 1998-03-03 Bayer Corporation Fibrinogen binding peptides
US6207397B1 (en) * 1996-04-18 2001-03-27 Ariad Pharmaceuticals, Inc. In vitro fluorescence polarization assay
US5994309A (en) * 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
US5981254A (en) * 1997-10-30 1999-11-09 Haemacure Corporation Process for producing thrombin from plasma
JP2002501084A (en) * 1998-01-23 2002-01-15 シーエスエル、リミテッド Purification of fibrinogen
IL128193A (en) * 1999-01-22 2008-03-20 Yeda Res & Dev Rhamnosyl-transferase gene and uses thereof
EP2975127A1 (en) 1999-10-29 2016-01-20 GlaxoSmithKline Biologicals SA Neisserial antigenic peptides
AU4309201A (en) * 1999-12-02 2001-06-12 V.I. Technologies, Inc. Method of identifying a ligand for a target molecule
US20030232054A1 (en) * 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
WO2001069258A1 (en) * 2000-03-16 2001-09-20 Biacore Ab Method for capturing analytes eluted from surface-bound ligands
EP1276849A4 (en) * 2000-04-12 2004-06-09 Human Genome Sciences Inc Albumin fusion proteins
US7892854B2 (en) * 2000-06-21 2011-02-22 Bioarray Solutions, Ltd. Multianalyte molecular analysis using application-specific random particle arrays
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
US7022486B2 (en) * 2001-08-13 2006-04-04 Douglas A. Campbell Peptide sequence tags and method of using same
WO2003083436A2 (en) * 2002-03-26 2003-10-09 Dyax Corp. Fibrinogen binding moieties
AU2003225008A1 (en) * 2002-04-15 2003-11-03 American National Red Cross Plasma protein-binding ligands
EP1616025B1 (en) * 2003-04-17 2007-09-12 The American National Red Cross Fluorescent substrates for detecting organophosphatase enzyme activity

Also Published As

Publication number Publication date
CA2482856A1 (en) 2003-10-30
US20080160501A1 (en) 2008-07-03
WO2003088990A1 (en) 2003-10-30
EP1494695A1 (en) 2005-01-12
AU2003225008A1 (en) 2003-11-03
HK1082040A1 (en) 2006-05-26
US20030212253A1 (en) 2003-11-13
US7217507B2 (en) 2007-05-15
AU2003231731A1 (en) 2003-11-03
CN100525829C (en) 2009-08-12
EP1495318A1 (en) 2005-01-12
EP1495318A4 (en) 2008-05-21
CN1659432A (en) 2005-08-24
EP1494695A4 (en) 2006-01-25
JP4585766B2 (en) 2010-11-24
US20030211471A1 (en) 2003-11-13
WO2003089922A1 (en) 2003-10-30
CA2482529A1 (en) 2003-10-30
JP2005522712A (en) 2005-07-28
US20090258834A1 (en) 2009-10-15
US7223734B2 (en) 2007-05-29

Similar Documents

Publication Publication Date Title
WO2003089922A8 (en) Method for detecting ligands and targets in a mixture
WO2000058870A3 (en) Handling a request for information provided by a network site
CA2235269A1 (en) Monoclonal antibody br110 and uses thereof
AU2001257012A1 (en) Methods for selective targeting
WO2000002917A3 (en) Compounds and methods for modulating cadherin-mediated functions
WO2002074249A3 (en) Pharmaceuticals and methods for treating hypoxia and screening methods therefor
WO2003020880A3 (en) Method of identifying inhibitors of lck
WO2004091523A3 (en) Method for identifying ligands specific for structural isoforms of proteins
WO2007066109A8 (en) Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
WO2006052842A3 (en) Methods for diagnosis of myelodysplastic syndromes (mds)
AU6249299A (en) Apparatus and method of configuring target areas within a touchable item of a touchscreen
WO2006031986A3 (en) Methods and compositions for diagnosing neoplastic disease
FR2853077B1 (en) SOLID PHASE IMMUNOCHROMATOGRAPHIC METHODS
AU2003302527A1 (en) Nmr-based methods for detecting ligands, where the ligand or target are hyperpolarised and the nmr-spectrum is compared with a reference spectrum of the ligand or target
WO2000062074A8 (en) Use of 13c-nmr to detect binding
WO2000075657A3 (en) Screening of target-ligand interactions
AU2001296830A1 (en) Ligand based solution assay for low concentration analytes
SE9300090D0 (en) AFFINITY CLEANING WITH COMPLEX BOND LIGAND
WO2004039963A8 (en) Antibodies specific for phosphorylated insulin receptor substrate-1/2 (ser 1101/ser1149) and uses thereof
EP1483561A4 (en) Light-emitting fusion proteins and diagnostic and therapeutic methods therefor
WO2001072778A3 (en) Method of identifying inhibitors of tie-2
AU5924699A (en) Methods for identifying hot-spot residues of binding proteins and small compounds that bind to the same
WO2003091415A3 (en) Fluorobodies and chromobodies: binding ligands with intrinsic fluorescence and color
WO2004081531A3 (en) Ligand analysis
WO2006078733A3 (en) Estrogen receptor structure

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 2003231731

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003586604

Country of ref document: JP

Ref document number: 2482529

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003747009

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038137275

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003747009

Country of ref document: EP